U
INFI

UBS’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

UBS’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
500
-20,512
-98% -$244K ﹤0.01% 9194
2014
Q2 		$268K Buy
21,012
+20,512
+4,102% +$214K ﹤0.01% 4857
2014
Q1 		$6K Hold
500
– – ﹤0.01% 9413
2013
Q4 		$7K Buy
+500
New +$7.06K ﹤0.01% 9352

Other funds holding INFI

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS's INFI Position: Q3 2014 in Review

UBS reduced its Infinity Pharmaceuticals, Inc. (INFI) stake by 98% in Q3 2014, selling an estimated $244K and leaving 500 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #9194.

UBS first reported a position in INFI in Q4 2013 and has held it in 4 quarters since. The position peaked at $268K in Q2 2014. 118 funds tracked by Wall St. Rank hold INFI as of Q3 2014.

  • UBS held 500 shares of Infinity Pharmaceuticals, Inc. worth $7K as of Q3 2014.
  • UBS sold 20,512 Infinity Pharmaceuticals, Inc. shares in Q3 2014, an estimated $244K.
  • Infinity Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9194 holding.
  • UBS first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2013 and has held it in 4 quarters since.
  • UBS's Infinity Pharmaceuticals, Inc. position peaked at $268K in Q2 2014.
  • 118 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.